Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Prices $850M Senior Notes Offering

NEW YORK – Agilent Technologies said on Wednesday evening that it has priced a public offering of its senior notes in an aggregate principal amount of $850 million.

Agilent expects the net proceeds of the offering to be about $841.1 million and the offering to close on Mar. 12.

The Santa Clara, California-based firm plans to use the net proceeds to fund the redemption of its 3.20 percent senior notes due in 2022, to pay down borrowings under its commercial paper program, and for general corporate purposes.

Barclays Capital, Citigroup Global Markets, and JP Morgan Securities are acting as joint book-running managers on the offering.

The notes will mature in March 2031 and will bear interest at an annual rate of 2.3 percent.

Earlier this week, Agilent said it plans to acquire liquid biopsy firm Resolution Bioscience for up to $695 million.

Agilent's shares were down about 1 percent at $118.19 in Thursday morning trading on the New York Stock Exchange.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.